Scinai Immunotherapeutics Ltd ADR SCNI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
-
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
-
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
-
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Trading Information
- Previous Close Price
- $0.25
- Day Range
- $0.23–0.26
- 52-Week Range
- $0.21–3.48
- Bid/Ask
- $0.22 / $0.29
- Shares Outstanding
- 5.17M
- Market Cap
- $1.27M
- Volume/Avg
- 140 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.57
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 45
- Website
- https://www.scinai.com
Valuation
|
Metric
|
SCNI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.14 |
Price/Sales | 0.57 |
Price/Cash Flow | — |
Price/Earnings
SCNI
Financial Strength
|
Metric
|
SCNI
|
|---|---|
Quick Ratio | 1.29 |
Current Ratio | 1.35 |
Interest Coverage | −5.87 |
Quick Ratio
SCNI
Profitability
|
Metric
|
SCNI
|
|---|---|
Return on Assets (Normalized) | −65.45% |
Return on Equity (Normalized) | −247.84% |
Return on Invested Capital (Normalized) | −71.10% |
Return on Assets
SCNI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yQ!<Y? | LOCK|&&p$P | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Kn<c>K% | LOCK|NZ?R! | $71B | |||
| argenx SE ADR
ARGX
| LOCK|yT!>Y& | LOCK|?@f | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|NRY#!@L | LOCK|MPK | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|R>cWGB | LOCK|N#dV | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kh!@?q&< | LOCK|nLqBh | $26B | |||
| Moderna Inc
MRNA
| LOCK|yHhzrJ | LOCK|tc% | $25B | |||
| Incyte Corp
INCY
| LOCK|WTDp%v | LOCK|#p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|nvS!%F? | LOCK|T& | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%%k>$> | LOCK|^FQ | $16B |
United States